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ProteaseDipeptidyl peptidase 4 is an important drug target for diabetes and a novel adipokine. However, it is
unknown how soluble DPP4 (sDPP4) is cleaved from the cell membrane and released into the circu-
lation. We show here that MMP1, MMP2 and MMP14 are involved in DPP4 shedding from human
vascular smooth muscle cells (SMC) and MMP9 from adipocytes. Hypoxia increased DPP4 shedding
from SMC which is associated with increased mRNA expression of MMP1. Our data suggest that
constitutive as well as hypoxia-induced DPP4 shedding occurs due to a complex interplay between
different MMPs in cell type-speciﬁc manner.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Dipeptidyl peptidase 4 (DPP4) is a glycoprotein of 110 kDa,
which is ubiquitously expressed on different cell types. The extra-
cellular part of this type II cell surface protein is substantially gly-
cosylated, which plays an important role in the interaction with
different proteins [1]. As an exopeptidase of the serine protease
type, DPP4 cleaves numerous substrates at the penultimate posi-
tion and thereby mostly inactivates them. Among these are pep-
tides (e.g. stromal cell-derived factor 1 alpha (SDF1a), eotaxin)
and cytokines (monocyte chemotactic protein-1 (MCP-1), interleu-
kin 2 (IL-2)) as well as the incretin hormones [1]. The incretin
hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are major regulators of the post-
prandial insulin release [2]. Therefore gliptins, a class of speciﬁc
DPP4 inhibitors, are now widely used as a monotherapy orcombination therapy for type 2 diabetes. By inhibition of DPP4
activity, these drugs prolong the half-life of GLP-1 and GIP which
then stimulate pancreatic insulin secretion, suppress glucagon
production and thereby contribute to an improved glycemic
control [2,3].
DPP4 is not only present on the surface of cells, but can also
be found in the circulation [4]. By comprehensive proteomic
proﬁling of the adipocyte secretome, we could identify soluble
DPP4 (sDPP4) as a novel adipokine, with an upregulated release
throughout the differentiation of adipocytes [5,6]. We conﬁrmed
that mature adipocytes in comparison to macrophages and
preadipocytes are a major source of DPP4 [5]. Elevated serum
levels of DPP4 were found in obese patients and correlate with
the size of adipocytes and risk factors for the metabolic
syndrome.
It has been reported, that DPP4 as a type II transmembrane pro-
tein is cleaved of the cell membrane in a process called shedding
[7]. The nature of enzymes contributing to the shedding of DPP4
and the regulation of this process is largely unknown. The aims
of our study were to elucidate the underlying shedding mechanism
and to explore the regulation of sDPP4 release in vitro. We show
here for the ﬁrst time that members of the metalloprotease family
are involved in the release of sDPP4 from different primary human
cells.
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2.1. Materials
Complete protease inhibitor (04693116001), and PhosStop
phosphatase (04906837001) inhibitor cocktail were provided by
Roche. Reagents for SDS–PAGE were supplied by Amersham Phar-
macia Biotech and by Sigma. DPP4 rabbit polyclonal antibody
(H00001803-D01P) was obtained from Abnova. Beta actin mouse
antibody (ab6276) was supplied by Abcam. HRP-conjugated goat
anti-rabbit (W4011) and goat anti-mouse (W4021) IgG antibodies
where purchased from Promega.
Collagenase NB4 (17465.02) was obtained from Serva. FCS
(10270-106), Dulbecco’s modiﬁed Eagles/HAM F12 (DMEM/F12)
medium (42400-010), a-modiﬁed Eagle’s (a MEM) medium
(11900-016) and Ham’s F-12 medium (21700-026) was supplied
by Gibco (Invitrogen). Troglitazone was obtained from Sigma
Aldrich.
The Protease inhibitors AEBSF (ALX-270-022), E64 (ALX-260-
007) were dissolved in water. BB-94 (196440), MMP9 Inhibitor I
(444278) and MMP2 Inhibitor III (444288) were purchased from
Calbiochem and dissolved in sterile DMSO. Human Protease Array
Kit (ARY021) was obtained from R&D Systems.
2.2. Adipocyte isolation and culture
Preadipocytes of human subcutaneous adipose tissue were
obtained from lean or moderately overweight subjects undergoing
plastic surgery. Isolation was performed as previously described
[8]. Cells from up to passage 4 were grown to conﬂuence in
Dulbecco’s modiﬁed Eagle’s medium/Ham’s F12 (DMEM/F12)
supplemented with 10% FCS with medium change every 2-3 days.
Passaging of the preadipocytes was performed according to Skurk
et al. [9]. Differentiation was started by adding 5 lmol/l troglitaz-
one for 3 days to adipocyte differentiation medium (DMEM/F12,
33 lmol/l biotin, 17 lmol/l D-panthothenic-acid, 66 nM insulin,
1 nM triiodo-L-thyronine, 100 nM cortisol, 10 lg/ml apo-transfer-
rin, 50 lg/ll gentamycin, 15 mmol/l HEPES, 14 nmol/l NaHCO3,
pH 7.4) as described previously [5]. After 14 days cells where trea-
ted with the indicated substances diluted in a-modiﬁed DMEM
and incubated for the indicated periods.
2.3. Smooth muscle cell culture
Primary human smooth muscle cells (SMC) from three different
donors (Caucasian, one male, two females) were supplied as prolif-
erating cells from Lonza, TebuBio and PromoCell and kept in culture
according to the manufacturer’s protocol. For all experiments sub-
conﬂuent cells of passage three were used. SMC were characterized
by morphologic criteria and by immunostaining with smooth mus-
cle a-actin. For the experiments 100.000 cells/ml were seeded and
grown for 24 hours in Growth medium (Promocell) with appropri-
ate supplements. After washing with PBS and serum starvation for
24 hours cells were treated as indicated.
2.4. Hypoxia
For hypoxic experiments, cells were exposed to 1% O2 supple-
mented with 5% CO2 and respective concentrations of nitrogen in
an Xvivo hypoxia chamber system (Biospherix) for 24 or 48 h.
2.5. ELISA
DPP4 release to the cell culture medium was measured by
human DPP4 DuoSet ELISA (R&D Systems, DY1180) according to
the manufacturer’s instructions.2.6. Silencing of target genes
SMC were seeded in 6-well plates and grown until 60–80%
conﬂuence. Silencing experiments were performed by using
40 nM FlexiTube siRNA (Qiagen, MMP1 (SI03021802), MMP14
(SI03648841)) and 12 ll HiPerfect (Qiagen, 301705) according to
the manufacturers’ instructions. At day 10-12 of differentiation
adipocytes were treated with 40 nM of the respective siRNA and
9 ll of HiPerfect. Optimal transfection conditions were tested by
separate titration experiments. To control for unspeciﬁc effects,
control cells were treated with AllStars Negative Control siRNA
(QIAGEN, 1027280). After 24 h mRNA was isolated to check for
silencing efﬁciency. Supernatants were collected after 24 or 48 h
respectively.
2.7. qRT-PCR
Total RNA was isolated and reverse transcribed using the
RNeasy Mini Kit (Qiagen, 74106) and Omniscript Reverse
Transcription kit (Qiagen, 205113) according to the manufacturer’s
instructions. Gene expression was determined by quantitative
real-time PCR (qRT PCR) using QuantiTect primer assays (Qiagen,
ACTB, QT00057428, QT00001533, QT00040040, QT00088396,
QT00014581, QT00055580) and GoTaq qPCRMaster Mix (Promega,
A6002) with 0.04-0.4 ng of generated cDNA on a Step One Plus
Cycler (Applied Biosystems). Beta-actin was used as a reference
gene and expression levels of investigated genes were normalized
to beta-actin. Gene expression was analyzed via the DDCt method
and compared with the designated control.
2.8. Statistical analysis
Data are expressed as mean ± SEM. Unpaired two-tailed
Student’s t test or one-way ANOVA (post hoc test: Bonferroni’s
multiple comparison test) were used to determine statistical sig-
niﬁcance. All statistical analysis was done using Prism (GraphPad,
La Jolla, CA, USA) considering a P value of less than 0.05 as statisti-
cally signiﬁcant. Corresponding signiﬁcance levels are indicated in
the ﬁgures.
3. Results
3.1. sDPP4 release is insensitive to brefeldin A treatment
In accordance with previously published data on sDPP4 release
from skeletal muscle cells [10], sDPP4 release did not follow the
classical ER/Golgi-dependant pathway in SMC and adipocytes,
because it was insensitive to brefeldin A (bref A) treatment
(Fig. 1A and B). The applied concentrations of bref A were effective
in blocking IL-6 secretion from SMC (Fig. 1A) and adiponectin
secretion from adipocytes (Fig. 1B).
3.2. Protease proﬁle differs between SMC and adipocytes
To ﬁnd out what types of proteases are released from different
cell types and if there is a difference in the release proﬁle of prote-
ases, we used supernatants of adipocytes and SMC in a Protease
Proﬁler Array. This array enables us to assess the release of 34 dif-
ferent proteases of the four main types of proteases, namely matrix
metalloproteases (MMP), serine proteases, cysteine proteases and
aspartyl proteases. A huge panel of proteases spotted on this mem-
brane belongs to the Cathepsins, which are serine, cysteine or
aspartyl proteases. The comparison of different members of the
Cathepsin family showed, that the detectable subtypes were more
or less identical in the different cell types (Data not shown). In
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Fig. 1. Inﬂuence of bref A treatment on sDPP4 release in SMC (A) and adipocytes (B). Cells were treated for 24 h with indicated concentrations of bref A. sDPP4 release and IL-6
or adiponectin secretion respectively to the culture medium was measured by ELISA. Data are mean values ± SEM, n = 3-4; ⁄P < 0.05, ⁄⁄⁄P < 0.001 vs. non-treated control; n.s.
not signiﬁcant; bref A, brefeldin A.
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whereas in adipocytes MMP2 and MMP9 signals were the stron-
gest for all MMPs tested in the array (Fig. 2 B).
3.3. sDPP4 release can be reduced by general broad spectrum protease
inhibitors
To identify the proteolytic enzymes involved in the DPP4 shed-
ding, different classes of protease inhibitors were screened for their
ability to block sDPP4 release. In SMC, sDPP4 release was impaired
by the general broad spectrum MMP inhibitor BB-94, the general
cysteine protease inhibitor E64 and the general serine protease
inhibitor AEBSF to the same extent (Fig. 3A). To elucidate if a com-
bination of these inhibitors could further diminish sDPP4 release,
E64 and AEBSF, E64 and BB-94 as well as AEBSF and BB-94 were
combined. None of these combinations showed additive effects
on sDPP4 release (Fig. 3B). Furthermore, none of the treatments
affected DPP4 protein expression (data not shown).
In adipocytes, only BB-94 showed a signiﬁcant effect on sDPP4
release (Fig. 3A). In the combination of the different classes of
inhibitors no additive effects were observed (Fig. 3B). The protein
expression of DPP4 remained unchanged after treatment with
the different classes of protease inhibitors (data not shown).
3.4. sDPP4 release is mediated by metalloproteases
To correlate the shown effects of the general MMP inhibitor to a
subset of MMPs, speciﬁc inhibitors or gene silencing were used.
The IC50 values of BB-94 are lowest for MMP14 (2 nM), MMP1(3 nM), MMP2 and MMP9 (4 nM) and some of these MMPs are ele-
vated in mouse models of obesity [11,12]. To deduce our ﬁndings
with BB-94 to a speciﬁc MMP, we used speciﬁc inhibitors if avail-
able or gene silencing if no speciﬁc inhibitors could be used.
Expression of the respective MMP could be reduced by about 70–
80% using speciﬁc siRNAs (Suppl. Fig. 1). In SMC, inhibition of
MMP2 and silencing of MMP1and MMP14 showed the most prom-
inent effects on sDPP4 release, which was blocked by 20-30%,
respectively (Fig. 4A). Inhibition of MMP9 in SMC showed only a
slight effect on sDPP4 release (Fig. 4A). In contrast to SMC,
MMP2 inhibition did not affect sDPP4 release in adipocytes, but
MMP9 inhibition signiﬁcantly reduced DPP4 shedding (Fig. 4B).
Silencing of MMP1 or MMP14 in adipocytes had no effect on
DPP4 shedding (Fig. 4B).
3.5. Hypoxia increases DPP4 shedding from SMC
To test whether lower oxygen levels can inﬂuence DPP4 shed-
ding, SMC were incubated in an Xvivo hypoxia chamber system
at 1% and 21% O2 for 24 or 48 h. After 24 h as well as after 48 h
sDPP4 release was upregulated between 40% and 50%, respectively
(Fig. 5A). However, DPP4 mRNA levels were not signiﬁcantly ele-
vated compared to normoxic conditions (Fig. 5B).
In addition to DPP4 shedding, mRNA expression of selected
MMPs was tested after challenging of the SMC with 1% O2. The
most prominent effect of hypoxia could be shown for the expres-
sion of MMP1, which was upregulated more than 3-times by
hypoxia-treatment after 48 h in SMC. Even after 24 h, mRNA levels
increased 2-fold in the hypoxic situation (Fig. 5C). MMP9 mRNA
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(Fig. 5C). A slight but signiﬁcant increase was also detected after
48 h for the expression of a disintegrin and metalloprotease
(ADAM)17/tumor necrosis factor a converting enzyme (TACE)
(Fig. 5C). In contrast, expression of MMP2 and MMP14 remained
comparable to normoxic conditions (Data not shown).
Additional protease arrays were performed using supernatants
from SMC cultured under hypoxic and normoxic conditions. Prote-
ase array results conﬁrmed that hypoxia increased relative sDPP4
release and indicate that the increased expression of MMP1 mRNA
is paralleled by increased MMP1 release (Data not shown).4. Discussion
DPP4 is a type II transmembrane glycoprotein that is released
from the membrane in a non-classical secretion mechanism. This
is evidenced by insensitivity to brefeldin A treatment and the lack
of a cleavable signal sequence at the N-terminus [13,14]. Type II
single-pass transmembrane proteins possess a signal anchor
sequence which is positioned within the membrane-spanning
domain and which targets these proteins to the rough endoplas-
matic reticulum. But in contrast to a classical secreted protein,
the signal for the peptidase which cleaves off the signal sequence
is missing [15]. We were able to conﬁrm, that DPP4 is insensitive
to brefeldin A treatment not only in skeletal muscle cells [10],
but also in SMC and adipocytes. Endogenous proteolytic release
of transmembrane proteins is limited to type I or type II transmem-
brane proteins. This occurs by post-translational hydrolysis, the so
called shedding [7]. Bioinformatic analysis with Secretome 2.0 pre-
dicted DPP4 as non-classically secreted protein with a score of
0.719 (exceeding the threshold of 0.5). The cleavage of sDPP4 most
likely occurs in the spacer region spanning amino acid 29–39 of the
full length DPP4 according to the protein annotation at UniProt.
However, the responsible enzymes are unknown so far.
Our data suggest that various types of proteases are able to
induce sDPP4 release, because DPP4 shedding was signiﬁcantly
reduced by general serine-(AEBSF), cysteine-(E64) and metallopro-
tease (BB-94) inhibitors in SMC. Because combined treatment with
the effective broad spectrum protease inhibitors lead to no additive
effects we speculate, that in case of sDPP4 release a proteolytic cas-
cade which involves cathepsins and MMPs could be supposed. This
goes in line with the rather complex activation of MMPs. MMPs
belong to the family of zinc-dependent enzymes which are synthe-
sized as an inactive proenzyme released into the extracellular
space. Propeptides of MMPs are covalently bound to the zinc ion
in the active center of these enzymes and thereby suppress the
enzymatic activity until the propeptide is cleaved off [16]. Different
factors are able to activate MMPs like urokinase-type plasminogen
activator (uPA), coagulation factors, phorbol esters or cytokines
[16]. But even MMPs can activate each other, which is known in
case of MMP2 activation by MMP14 [17] or MMP9 activation by
MMP2 and MMP3 [18]. Also serine proteases like plasmin and kal-
likreins or cysteine proteases like Cathepsin G were shown to
directly activate MMP1, MMP2 and MMP9 in vitro or in vivo [19].
For MMP2, MMP9 and MMP14 it has already been reported,
that their expression levels are elevated in obese mice [11,12].
Furthermore MMP1, MMP2, MMP9 and MMP14 play a role in
the shedding of a large variety of substrates [20–24]. These stud-
ies also emphasize that one MMP can shed several substrates and
shedding of a speciﬁc target might not be limited to a speciﬁc
MMP, but is a rather complex interplay between different
enzymes.
Our results suggest that MMP1, MMP2 and MMP14 play a role
in constitutive DPP4 shedding in SMC. One may keep in mind that
MMP14 is able to activate MMP2 [17] and therefore might not onlydirectly contribute to DPP4 shedding in vitro. Proteome proﬁler
array data conﬁrmed that MMP2 and MMP1 are released by SMC,
whereas MMP9 was below the detection level in the supernatants
of unstimulated SMC. Although also MMP3 was released from SMC,
we did not further investigate this MMP due to the following rea-
sons. First, MMP3 is described as a protective MMP in the context
of atherosclerosis and it is not clear if this MMP is involved in shed-
ding processes [25,26]. Furthermore the IC50 of BB-94 for MMP3 is
signiﬁcantly higher in comparison to the other candidates. In
adipocytes only the speciﬁc inhibition of MMP9 could decrease
DPP4 shedding, whereas MMP2 inhibition, MMP1 or MMP14
silencing respectively showed no effect. MMP1, MMP2 and
MMP9 were detectable in the unstimulated supernatants of adipo-
cytes. This result suggests, that constitutive DPP4 shedding is cell-
type speciﬁc. None of the investigated mechanisms to block MMPs
where able to reduce DDP4 release below 50%, which indicates,
that DPP4 shedding is not only regulated by a single MMP.
We were able to demonstrate that low oxygen levels of 1% O2
increase DPP4 shedding in SMC. In developing lesions during ath-
erogenesis the oxygen supply is often exhausted, which is partly
due to the highly oxygen-consuming foam cells and the relatively
low diffusion rate of oxygen through the cell environment [27].
This can result in severe hypoxia (< 1% O2) in some areas. Hypoxia
affects transcription of genes, which are for example responsible
for matrix remodeling [28]. For some MMPs like MMP1 and
MMP9, it is already known that hypoxia stimulates their release
and expression [29,30]. In our setting, we were able to show an
increased expression of MMP1, MMP9 and ADAM17/TACE under
low oxygen supply. MMP1 release was relatively high in SMC com-
pared to other MMPs, whereas it was relatively low in adipocytes.
Therefore, MMP1 might be an important player in DPP4 shedding
both under normoxic and particularly under hypoxic conditions
in SMC. Though MMP9 mRNA expression is also upregulated due
to hypoxia, this MMP could only play a minor role in DPP4 shed-
ding in SMC, because it is barely detectable in supernatants of
these cells compared to supernatants from adipocytes as shown
by the Protease Array Analysis. Furthermore, MMP9 inhibition
had only a very slight effect on DPP4 shedding. MMP2, which
showed an impact on sDPP4 release after treatment with a speciﬁc
inhibitor, was not inﬂuenced by hypoxia. ADAM17/TACE, cannot be
ruled out to be involved in DPP4 shedding. From the literature it is
known that it is involved in the processing of different substrates
despite its eponymous target TNFa [31]. Although we were able
to silence ADAM17/TACE in SMC using different siRNAs, we always
observed a concomitant upregulation of MMP1 thus preventing us
from clarifying the role of ADAM17/TACE in DPP4 shedding. As no
speciﬁc ADAM17/TACE inhibitor is available, it is unfortunately
impossible to further study ADAM17/TACE at the moment. In the
end, DPP4 expression itself is not inﬂuenced by hypoxia which
shows, that the increased release of sDPP4 is not due to a higher
DPP4 expression, but seems to be mediated at the level of DPP4
processing. In adipocytes, we could already show that culture at
1% O2 for 24 h had no effect on DPP4 release [5].
Adipose tissue and immune cells are recognized sources of
DPP4. Circulating DPP4 concentrations are not only higher in obese
patients but also in various inﬂammatory diseases [4,32]. In a
previous study, we were already able to show a signiﬁcantly
decreased DPP4 release from adipose tissue explants and in serum
from obese patients who underwent bariatric surgery [5]. MMP2
and MMP9 are key elements of extracellular matrix modulation
in adipose tissue and both MMPs are signiﬁcantly higher in serum
of obese patients [33] and MMP2 is signiﬁcantly downregulated in
serum of patients after bariatric surgery [34]. High serum and
mRNA expression levels of MMP1 and MMP9 are also associated
with carotid atherosclerosis and plaque stability in patients
[35–37]. Accordingly, patients with a higher risk for cardiovascular
3876 D. Röhrborn et al. / FEBS Letters 588 (2014) 3870–3877disease are characterized by both higher circulating DPP4 and
increased serum levels of MMP1 [38,39]. In vitro, we have previ-
ously shown that sDPP4 in concentrations similar to circulating
levels induces SMC proliferation [5]. In parallel, sDPP4 induces
inﬂammatory and stress pathways in vascular cells [40,41].
Accordingly, sDPP4 generated in ischemic tissue or derived from
perivascular and visceral adipose tissue might have similar effects
in vivo [32,42]. The multiple targets and functions of DPP4 and its
inhibition by gliptins suggest that it could also play an important
role beyond its effects on the incretin axis [43]. As for the relation
of DPP4 and potential shedding enzymes of DPP4 to obesity and
atherosclerosis, it should be noted that only correlative data is
available at the moment and no causal relationship can be estab-
lished based on our current knowledge. In the future, research
should focus on the molecular mechanisms of DPP4 shedding in
the context of atherosclerosis and obesity which might ﬁnally help
to better understand the role of sDPP4 in physiological and patho-
physiological conditions.
In conclusion, we could show that several MMPs are involved in
the constitutive DPP4 shedding as well as under hypoxic condi-
tions in vitro. Our data suggest, that not a single MMP is involved
in sDPP4 release, but it is rather an interplay between different
shedding enzymes in a cell type-speciﬁc manner.
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